中国经济网北京9月5日讯百克生物(688276.SH)近期发布2025年半年度报告。2025年上半年，公司实现 营业收入2.85亿元，同比下滑53.93%；归属于上市公司股东的净利润-7357.34万元，去年同期为1.38亿 元；归属于上市公司股东的扣除非经常性损益的净利润-8223.24万元，去年同期为1.35亿元；经营活动 产生的现金流量净额为931.93万元。 百克生物本次上市发行费用为1.05亿元，其中，保荐机构、主承销商中信证券股份有限公司和联席主承 销商国泰君安证券股份有限公司获得承销保荐费9004.06万元。 本次发行最终战略配售数量为825.61万股，约占发行总数量的20.00%，与初始战略配售数量的差额744 股回拨至网下发行。依据《上海证券交易所科创板股票发行与承销业务指引》第十八条规定，本次发行 保荐机构相关子公司中信证券投资有限公司最终获配股份数量为165.06万股，获配金额6000.00万元。 百克生物于2021年6月25日在上交所科创板上市，公司公开发行股票数量为4128.41万股，占本次发行后 总股本的10.00%，发行价格为36.35元/股，保荐机构为中信证券股份有限公司，保荐 ...

Core Viewpoint - Changchun High-tech reported strong financial performance for 2024, with significant revenue and profit growth, alongside a robust commitment to R&D and shareholder returns [1][5] Financial Performance - The company achieved operating revenue of 13.466 billion yuan and a net profit of 2.583 billion yuan for the reporting period [1] - Basic earnings per share were reported at 6.42 yuan, with a cash dividend of 26 yuan per 10 shares (tax included) [1] - For Q1 2025, the company reported operating revenue of 2.997 billion yuan and a net profit of 473 million yuan, with basic earnings per share of 1.17 yuan [5] R&D Investment - R&D investment reached 2.690 billion yuan, an increase of 11.20% year-on-year, accounting for 19.97% of operating revenue [1] - R&D expenses were 2.167 billion yuan, up 25.75% from the previous year, driven by accelerated new product development and talent acquisition [1][2] Product Development and Market Expansion - The company has 24 key products in clinical stages, with several new products receiving registration certificates and market approvals [2] - In 2024, Changchun High-tech accelerated international sales of growth hormone products, achieving sales revenue of 99 million yuan in foreign markets, a 454% increase year-on-year [2] Strategic Focus - The company aims to enhance new drug development capabilities, focusing on high-growth and high-value areas, while ensuring project management and market-driven innovation [3] - Plans include advancing vaccine development for infectious disease prevention and control, with a focus on high-demand human vaccines [3] AI Integration - Changchun High-tech is integrating AI technology into its R&D and management processes, enhancing efficiency across drug discovery, design, and production [4] - The company has made breakthroughs in antibody design using AI models, leading to cost reductions and improved production efficiency [4] Shareholder Returns - The company has established a three-year shareholder return plan, distributing a cash dividend of 4.5 billion yuan for 2023, totaling 1.847 billion yuan in cash dividends since its listing [5] - Cumulative cash dividends and share buybacks amount to 4.967 billion yuan, exceeding the total cash raised from various fundraising activities [5]